AI assistant
Sending…
BioLineRx Ltd. — Report Publication Announcement 2021
Aug 18, 2021
6692_rns_2021-08-18_42d63893-2c06-4ae9-a78c-8f6ccad9ef67.htm
Report Publication Announcement
Open in viewerOpens in your device viewer
_________ false
| ������� �� ��� ��"� | 2 379 |
| BIOLINE RX LTD | |
| Corporation no: 513398750 | 8688 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C001 ( Public ) | Reported via MAGNA: | 18/08/2021 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2021-02-133905 | Time of broadcast: 13:04 13:04 |
Report of Periodic or Interim ReportRegulation 3 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onSecond Quarter 2021 Financial Results and Provides Corporate Update
Second_Quarter_2021_Financial_Results_isa.pdf
Link to filing on foreign stock exchange (optional): _________
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 10/08/2021 |
| Address: HaMa'ayan 2 , Modi'in 7177871 , Israel Tel: 08-6429100 , Fax: 08-6429101 | |
| E-mail address: [email protected] Company site: www.biolinerx.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company: | |
| Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: [email protected] 1 | |
| Israel |
More from BioLineRx Ltd.
Regulatory Filings
2026
May 27
Report Publication Announcement
2026
May 27
Report Publication Announcement
2026
May 27
Report Publication Announcement
2026
May 24
Regulatory Filings
2026
May 24
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 19
Report Publication Announcement
2026
May 19
Regulatory Filings
2026
May 19
Regulatory Filings
2026
Apr 28